BDTX News and Press, Black Diamond Therapeutics Inc. From 10/04/23

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced fort...

2023-09-18 17:06:48 ET Gainers: Gain Therapeutics ( NASDAQ: GANX ) +7% . QuidelOrtho  ( QDEL ) +5% . ARS Pharmaceuticals ( SPRY ) +5% . ProFrac Holding  ( ACDC ) +5% . Clean Energy Fuels  ( CLNE ) +4% . L...

2023-09-18 07:45:37 ET More on Black Diamond Therapeutics Seeking Alpha’s Quant Rating on Black Diamond Therapeutics Biggest stock movers today: Icahn Enterprises, Stratasys, Chindata Group and more Black Diamond upgraded at Wedbush following lung cancer asset...

Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogen...

Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October 2023 CAMBRIDGE, Mass. and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developi...

2023-09-03 10:30:00 ET Summary We've compiled a list of August investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured here are the investm...

2023-08-11 07:43:48 ET Black Diamond Therapeutics press release ( NASDAQ: BDTX ): Q2 GAAP EPS of -$0.52 beats by $0.02 . Cash, cash equivalents, and investments of $89.5 million as of June 30, 2023; together with net proceeds from the July 2023 underwritten public offe...

Announced initial clinical data from dose-escalation portion of Phase 1 clinical trial of BDTX-1535, an EGFR MasterKey inhibitor, demonstrating a favorable tolerability profile and clinical proof of activity based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients...

2023-08-03 08:53:34 ET Summary Shares have risen by 94% so far in 2023 but have lost over three-quarters of their value since IPO at $19 in 2020. There is a clear unmet need in 2L NSCLC space post osimertinib, with a $500M+ opportunity contrasting favorably to the $75M enterprise ...

2023-07-27 08:38:28 ET Carmell Therapeutics  ( NASDAQ: CTCX ) +54% . Lipocine  ( LPCN ) +36% meets primary endpoint in Patients with cirrhosis. Celestica ( CLS ) +30% Q2 earnings call release Ultralife Corporation ( ULBI ) +30% Q...